In Cervical Cancer, The New Frontline SOC May Be Pembrolizumab/Chemo With or Without Bevacizumab
September 18th 2021In patients with persistent, recurrent, or metastatic cervical cancer the addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates.
TFI and PFS2 in Frontline Advanced Melanoma Improved With Relatlimab/Nivolumab
September 18th 2021In previously untreated patients with metastatic or unresectable melanoma, the addition of relatlimab to nivolumab prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone.
Osimertinib Continues to Impress With Response and Disease Control Rates in NSCLC
June 18th 2021Results from an observational, multicenter study that evaluated osimertinib reveal encouraging real-world efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer.
Phlebotomy Requirements Diminished With Rusfertide for Polycythemia Vera
June 15th 2021The hepcidin mimetic rusfertide is suggested to reduce the need for phlebotomy in patients with polycythemia vera, according to the results of the phase 2 PTG-300-04 trial presented during the European Hematology Association 2021 Virtual Congress.
Panitumumab Maintenance Combination Prolongs PFS in RAS Wild-Type mCRC
June 8th 2021In the phase 2 PANAMA trial, adding panitumumab to 5-fluorouracil and leucovorin showed significant improvement in progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.
Patritumab Deruxtecan Demonstrates Durable Efficacy in Heavily-Pretreated EGFR+ NSCLC Subset
June 5th 2021treatment with patritumab deruxtecan induced clinically meaningful, durable efficacy in heavily pretreated patients with EGFR-mutated non–small cell lung cancer who were resistant to EGFR tyrosine kinase inhibitors.
Zenocutuzumab Effectively Blocks Growth of NRG1 Fusion-Driven Tumors
April 10th 2021In NRG1 fusion–positive cell lines, zenocutuzumab demonstrated blockage of growth and cell death, as well as tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.
Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma
April 10th 2021In patient with metastatic uveal melanoma, frontline treatment with tebentafusp achieved significant and clinically meaningful improvement in overall survival, according to data from the phase 3 IMCgp100-202 trial.
OS Benefit Suggested for Frontline IO Versus TKIs in Metastatic Non–Clear Cell RCC
February 11th 2021A retrospective study has suggested that immunotherapy may have a great survival benefit in the frontline setting for patients with metastatic non–clear cell renal cell carcinoma (RCC) than select targeted therapies.
Beti-Cel Shows Good Activity in Transfusion-Dependent Children With Beta-Thalassemia
February 10th 2021Results from 2 phase 3 clinical trials showed that use of the investigational gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients under the age of 18 years with transfusion-dependent beta-thalassemia.